The holo beta‐lactoglobulin lozenge reduces symptoms in cat allergy—Evaluation in an allergen exposure chamber and by titrated nasal allergen challenge

Background The allergists´ tool box in cat allergy management is limited. Clinical studies have shown that holo beta-lactoglobulin (holoBLG) can restore micronutritional deficits atopic immune cells and alleviate allergic symptoms a completely allergen-nonspecific manner. With this study, we aimed to provide proof of principle allergy. Methods A novel challenge protocol for standardized ECARF allergen exposure chamber (AEC) was developed. In an open pilot study (NCT05455749), patients with clinically relevant were provoked 120 min the AEC before after 3-month intervention phase (holoBLG lozenge 2x daily). Nasal, conjunctival, bronchial, pruritus scored every 10 min– constituting total symptom score (TSS). Peak nasal inspiratory flow (PNIF) measured 30 min. addition, titrated provocation test (NPT) performed intervention. Primary endpoint change TSS at end final compared baseline. Secondary endpoints included changes PNIF, NPT, occurrence late reactions up 24 h exposure. Results 35 (mean age: 40 years) completed study. Compared baseline, holoBLG supplementation resulted significant improvement median 50% (p < 0.001), as well by 20 L/min = 0.0035). 20% reported baseline exposure, but 0% Conclusions Cat profited from targeted micronutrition lozenge. As previously seen other allergies, also induced resilience resulting amelioration.